Evidence map›Paper›PMID 21264074›Full record

ArticleExperimental and clinical cardiology2010

Mechanisms of the beneficial effects of beta-adrenoceptor antagonists in congestive heart failure.

Navneet S Rehsia, Naranjan S Dhalla

Abstract read
PubMed Full text at PMC
In one paragraph

Article in Experimental and clinical cardiology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Menstruation-Related Angina-The Wee Hours.The International journal of angiology : official publication of the International College of Angiology, Inc · 2024
    Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Navneet S RehsiaInstitute of Cardiovascular Sciences, St Boniface Hospital Research Centre;
Naranjan S Dhalla
St. Boniface Hospital · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Many clinical studies have documented favourable effects (reduced morbidity and mortality) of beta-adrenoceptor (β-AR) antagonists, such as carvedilol, metoprolol, propranolol, atenolol and bisoprolol, in congestive heart failure. These agents attenuate the effects of sympathetic activation during the development of heart failure, prevent ventricular remodelling and improve cardiac function. Because β-AR blockers are known to exert negative inotropic action, the mechanisms responsible for their beneficial effects in heart failure have been a subject of debate. While attenuation of changes in β-AR cyclic AMP-mediated signal transduction in heart failure is considered to be responsible for the beneficial effects of β-AR antagonists, other mechanisms such as the effects of these agents on subcellular remodelling, oxidative stress, apoptosis and defect in calcium handling, are equally important in preventing cardiac alterations in the failing heart. Moreover, β-AR antagonists are not a homogeneous group of drugs because they differ in their pharmacokinetics and pharmacodynamics, in addition to the selective and nonselective nature of their actions on β-AR. Various β-AR blocking agents have been shown to possess different ancillary properties and produce effects that are independent of β-AR. In fact, different β-AR antagonists have been observed to lower the elevated levels of plasma catecholamines in heart failure. Thus, the beneficial effects of β-AR antagonists are not only elicited through their interaction with mediated β-AR signal transduction sites in the myocardium, but other mechanisms may also contribute to their favourable actions in heart failure.

Indexed as

AtenololCarvedilolHeart failureMetoprololPropranololβ-adrenoceptor antagonists

Identifiers

PMID21264074
PMCPMC3016066
OpenAlexW2169884492

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.